AstraZeneca Pharma India (506820) Q3 25/26 earnings summary

Executive summary

• Reported 39% year-over-year revenue growth in Q3 FY25-26, driven by strong performance across Oncology, Biopharmaceuticals, and Rare Disease therapy areas.

• Achieved 8 new regulatory approvals in the past nine months, reinforcing leadership in key therapy areas.

• Continued disciplined execution, operational efficiency, and portfolio expansion contributed to growth.

Financial highlights

• Q3 FY25-26 revenue from operations: INR 6,115.7 million, up from INR 4,402.9 million in Q3 FY24-25.

• Profit before exceptional items and tax for Q3 FY25-26: INR 450.6 million; profit after exceptional items and tax: INR 326.0 million.

• Nine months ended Dec 31, 2025: revenue INR 16,969.7 million, profit after tax INR 1,426.4 million.

• Earnings per share (basic and diluted) for Q3 FY25-26: INR 13.04, up from INR 5.83 in Q3 FY24-25.

Outlook and guidance

• Management emphasizes continued focus on portfolio-driven growth, innovation, and expanding patient access.

• Ongoing efforts to strengthen the portfolio and deliver long-term value for patients in India.